Cinclus Pharma
Research based biotech company developing small molecules for the treatment of gastric acid related diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
* | SEK240m Valuation: SEK1.3b 159.1x EV/Revenue -8.0x EV/EBITDA | Private Placement VC | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | - | (30 %) |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (2001 %) | - |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | - | (2356 %) | (3564 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 1487 % | - |
Source: Company filings or news article
Related Content
Cinclus Pharma is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate, linaprazan glurate, is a novel treatment for erosive gastroesophageal reflux disease (eGERD), a condition that affects a significant portion of the population. Cinclus Pharma's business model revolves around the clinical development and subsequent commercialization of linaprazan glurate.
The company generates revenue through licensing and commercialization agreements. A notable partnership is the €220 million deal with Zentiva to bring linaprazan glurate to the European market. This agreement includes upfront and milestone payments, providing the company with capital to fund its ongoing Phase III clinical trials and other operational expenses. Cinclus Pharma targets the pharmaceutical market, specifically gastroenterology. The company has recently been listed on the Nasdaq Stockholm Main Market, enhancing its visibility and access to capital.
Keywords: pharmaceutical, linaprazan glurate, eGERD, clinical trials, drug development, gastroenterology, licensing agreement, biopharmaceutical, acid-related diseases, P-CAB